Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in Uruguay. Burutaran, M. B., Guadagna, R., Grille, S., Stevenazzi, M., Guillermo, C., & Diaz, L. Revista Brasileira de Hematologia e Hemoterapia, 37:28–33, February, 2015. Publisher: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in Uruguay [link]Paper  doi  abstract   bibtex   
Background: Febrile neutropenia is an important cause of mortality and morbidity in hematology-oncology patients undergoing chemotherapy. The management of febrile neutropenia is typically algorithm-driven. The aim of this study was to assess the results of a standardized protocol for the treatment of febrile neutropenia. Methods: A retrospective cohort study (2011-2012) was conducted of patients with high-risk neutropenia in a hematology-oncology service. Results: Forty-four episodes of 17 patients with a median age of 48 years (range: 18-78 years) were included. The incidence of febrile neutropenia was 61.4%. The presence of febrile neutropenia was associated with both the duration and severity of neutropenia. Microbiological agents were isolated from different sources in 59.3% of the episodes with bacteremia iso- lated from blood being the most prevalent (81.3%). Multiple drug-resistant gram-negative bacilli were isolated in 62.5% of all microbiologically documented infections. Treatment of 63% of the episodes in which the initial treatment was piperacillin/tazobactam needed to be escalated to meropenem. The mortality rate due to febrile neutropenia episodes was 18.5%. Conclusion: The high rate of gram-negative bacilli resistant to piperacillin/tazobactam (frontline antibiotics in our protocol) and the early need to escalate to carbapenems raises the question as to whether it is necessary to change the current protocol.
@article{burutaran_results_2015,
	title = {Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in {Uruguay}},
	volume = {37},
	issn = {1516-8484, 1806-0870},
	url = {https://www.scielo.br/j/rbhh/a/zv4nR8VvbqjLV3PCCvjzRkD/?format=html&lang=en},
	doi = {10.1016/j.bjhh.2014.11.012},
	abstract = {Background: Febrile neutropenia is an important cause of mortality and morbidity in hematology-oncology patients undergoing chemotherapy. The management of febrile neutropenia is typically algorithm-driven. The aim of this study was to assess the results of a standardized protocol for the treatment of febrile neutropenia. Methods: A retrospective cohort study (2011-2012) was conducted of patients with high-risk neutropenia in a hematology-oncology service. Results: Forty-four episodes of 17 patients with a median age of 48 years (range: 18-78 years) were included. The incidence of febrile neutropenia was 61.4\%. The presence of febrile neutropenia was associated with both the duration and severity of neutropenia. Microbiological agents were isolated from different sources in 59.3\% of the episodes with bacteremia iso- lated from blood being the most prevalent (81.3\%). Multiple drug-resistant gram-negative bacilli were isolated in 62.5\% of all microbiologically documented infections. Treatment of 63\% of the episodes in which the initial treatment was piperacillin/tazobactam needed to be escalated to meropenem. The mortality rate due to febrile neutropenia episodes was 18.5\%. Conclusion: The high rate of gram-negative bacilli resistant to piperacillin/tazobactam (frontline antibiotics in our protocol) and the early need to escalate to carbapenems raises the question as to whether it is necessary to change the current protocol.},
	language = {en},
	urldate = {2024-10-08},
	journal = {Revista Brasileira de Hematologia e Hemoterapia},
	author = {Burutaran, Matilde Boada and Guadagna, Regina and Grille, Sofia and Stevenazzi, Mariana and Guillermo, Cecilia and Diaz, Lilian},
	month = feb,
	year = {2015},
	note = {Publisher: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular},
	keywords = {Drug resistance, Gram-negative bacterial infections, Hematologic diseases, Neutropenia Clinical protocols, bacterial},
	pages = {28--33},
}

Downloads: 0